Biomea Fusion announced that it will present new clinical data from the ongoing Phase II portion of its COVALENT-111 trial, which is evaluating BMF-219 as a treatment for patients with type 2 diabetes, in a late-breaking poster presentation at the 2023 American Diabetes Association 83rd Scientific Sessions, to be held June 23 – 26, 2023 in San Diego, CA. The company will also host an investor and KOL event during the Scientific Session. Biomea will disclose additional information about the late-breaking presentation in accordance with ADA’s abstract embargo policies. In addition, the company will provide further details on the investor and KOL event at a later date.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BMEA:
- Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June
- Biomea Fusion price target lowered to $37 from $44 at H.C. Wainwright
- Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting
- Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Biomea Fusion closes upsized common stock offering of $172.5M